Showing results (31-40 of 54) with videos related to
Sort By:
Pageof 6
Frontiers in Pharmacology|May 21, 2016
From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of NaplesGaetano Facchini, Chiara Della Pepa, Carla Cavaliere, et al.Frontiers in Pharmacology|December 8, 2016
Corrigendum: Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Sabrina C Cecere, Sabrina Rossetti, Carla Cavaliere, et al.Cancers|March 13, 2024
Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?Francesco Perri, Roberta Fusco, Francesco Sabbatino, et al.Journal of Translational Medicine|September 8, 2023
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyDomenico Mallardo, Mario Fordellone, Andrew White, et al.Journal of Experimental & Clinical Cancer Research : CR|October 30, 2019
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1Crescenzo D'Alterio, Maria Buoncervello, Caterina Ieranò, et al.Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.Cancers|July 26, 2020
New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal CancerCrescenzo D'Alterio, Antonella Zannetti, Anna Maria Trotta, et al.Journal of Translational Medicine|September 30, 2022
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarizationDomenico Mallardo, Ester Simeone, Vito Vanella, et al.Journal for Immunotherapy of Cancer|November 24, 2022
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysisDomenico Mallardo, Diana Giannarelli, Maria Grazia Vitale, et al.Journal for Immunotherapy of Cancer|March 5, 2022
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapiesCaterina Ieranò, Dario Righelli, Crescenzo D'Alterio, et al.Pageof 6